125 related articles for article (PubMed ID: 30631260)
1. Whole Genome Sequencing Analysis of a Stage IV Colon Cancer Patient with a 10-Year Disease-Free Survival following Systemic Chemotherapy/Bevacizumab.
Yeatman TJ; Yang M; Coppola D
Case Rep Gastroenterol; 2018; 12(3):729-736. PubMed ID: 30631260
[TBL] [Abstract][Full Text] [Related]
2. Rapid response of stage IV colorectal cancer with APC/TP53/KRAS mutations to FOLFIRI and Bevacizumab combination chemotherapy: a case report of use of liquid biopsy.
Hendricks A; Rosenstiel P; Hinz S; Burmeister G; Röcken C; Boersch K; Schafmayer C; Becker T; Franke A; Forster M
BMC Med Genet; 2020 Jan; 21(1):3. PubMed ID: 31900123
[TBL] [Abstract][Full Text] [Related]
3. Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients.
van den Broek E; Krijgsman O; Sie D; Tijssen M; Mongera S; van de Wiel MA; Belt EJ; den Uil SH; Bril H; Stockmann HB; Ylstra B; Carvalho B; Meijer GA; Fijneman RJ
Oncotarget; 2016 Nov; 7(45):73876-73887. PubMed ID: 27729614
[TBL] [Abstract][Full Text] [Related]
4. [Case Report of Long-Term Survival for Stage IV Advanced Sigmoid Colon Cancer with Para-Aortic Nodes by R0 Resection and Chemotherapy].
Akai M; Otsuka S; Yasui Y; Isoda K; Hamano R; Tokunaga N; Takahashi K; Miyaso H; Tsunemitsu Y; Iwakawa K; Inagaki M; Iwagaki H
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1420-1422. PubMed ID: 29394654
[TBL] [Abstract][Full Text] [Related]
5. Multiple stage IV colorectal cancers in a patient who received multidisciplinary treatment, including chemotherapy and Japanese Kampo medicine: A case report.
Aomatsu N; Maeda K; Uchima Y; Matsutani S; Tsujio G; Miyamoto H; Okada T; Kurihara S; Nishii T; Tachimori A; Ikeda K; Takeuchi K
Neuropeptides; 2021 Aug; 88():102160. PubMed ID: 34004454
[TBL] [Abstract][Full Text] [Related]
6. Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy.
Tsunemitsu R; Tabuchi M; Sakamoto S; Ogi K; Matsumoto M; Iwata J; Okabayashi T
Surg Case Rep; 2023 Jun; 9(1):93. PubMed ID: 37266831
[TBL] [Abstract][Full Text] [Related]
7. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Sinicrope FA; Shi Q; Allegra CJ; Smyrk TC; Thibodeau SN; Goldberg RM; Meyers JP; Pogue-Geile KL; Yothers G; Sargent DJ; Alberts SR
JAMA Oncol; 2017 Apr; 3(4):472-480. PubMed ID: 28006055
[TBL] [Abstract][Full Text] [Related]
8. Primary tumor location and survival in colorectal cancer: A retrospective cohort study.
Aggarwal H; Sheffield KM; Li L; Lenis D; Sorg R; Barzi A; Miksad R
World J Gastrointest Oncol; 2020 Apr; 12(4):405-423. PubMed ID: 32368319
[TBL] [Abstract][Full Text] [Related]
9. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
[TBL] [Abstract][Full Text] [Related]
10. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
11. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.
Marisa L; de Reyniès A; Duval A; Selves J; Gaub MP; Vescovo L; Etienne-Grimaldi MC; Schiappa R; Guenot D; Ayadi M; Kirzin S; Chazal M; Fléjou JF; Benchimol D; Berger A; Lagarde A; Pencreach E; Piard F; Elias D; Parc Y; Olschwang S; Milano G; Laurent-Puig P; Boige V
PLoS Med; 2013; 10(5):e1001453. PubMed ID: 23700391
[TBL] [Abstract][Full Text] [Related]
12. Whole-exome sequencing identified mutational profiles of high-grade colon adenomas.
Lee SH; Jung SH; Kim TM; Rhee JK; Park HC; Kim MS; Kim SS; An CH; Lee SH; Chung YJ
Oncotarget; 2017 Jan; 8(4):6579-6588. PubMed ID: 28179590
[TBL] [Abstract][Full Text] [Related]
13. Retrospective Comparative Analysis of KRAS G12C
Giampieri R; Lupi A; Ziranu P; Bittoni A; Pretta A; Pecci F; Persano M; Giglio E; Copparoni C; Crocetti S; Mandolesi A; Faa G; Coni P; Scartozzi M; Berardi R
Front Oncol; 2021; 11():736104. PubMed ID: 34660299
[TBL] [Abstract][Full Text] [Related]
14.
Hsu HC; You JF; Chen SJ; Chen HC; Yeh CY; Tsai WS; Hung HY; Yang TS; Lapke N; Tan KT
Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31366114
[TBL] [Abstract][Full Text] [Related]
15. Genetic mutations associated with sensitivity to neoadjuvant chemotherapy in metastatic colon cancer: A case report and review of literature.
Zhao L; Wang Q; Zhao SD; Zhou J; Jiang KW; Ye YJ; Wang S; Shen ZL
World J Clin Cases; 2021 Aug; 9(24):7099-7109. PubMed ID: 34540965
[TBL] [Abstract][Full Text] [Related]
16. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
Fujita Y; Taguri M; Yamazaki K; Tsurutani J; Sakai K; Tsushima T; Nagase M; Tamagawa H; Ueda S; Tamura T; Tsuji Y; Murata K; Taira K; Denda T; Moriwaki T; Funai S; Nakajima TE; Muro K; Tsuji A; Yoshida M; Suyama K; Kurimoto T; Sugimoto N; Baba E; Seki N; Sato M; Shimura T; Boku N; Hyodo I; Yamanaka T; Nishio K
Oncologist; 2019 Mar; 24(3):327-337. PubMed ID: 30425180
[TBL] [Abstract][Full Text] [Related]
17. FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials.
Petrelli F; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Maspero F; Sauta MG; Beretta GD; Barni S
Clin Colorectal Cancer; 2013 Sep; 12(3):145-51. PubMed ID: 23763824
[TBL] [Abstract][Full Text] [Related]
18. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
Chibaudel B; Henriques J; Rakez M; Brenner B; Kim TW; Martinez-Villacampa M; Gallego-Plazas J; Cervantes A; Shim K; Jonker D; Guerin-Meyer V; Mineur L; Banzi C; Dewdney A; Dejthevaporn T; Bloemendal HJ; Roth A; Moehler M; Aranda E; Van Cutsem E; Tabernero J; Schmoll HJ; Hoff PM; André T; de Gramont A
JAMA Netw Open; 2020 Oct; 3(10):e2020425. PubMed ID: 33074326
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.
Matsusaka S; Hanna DL; Cao S; Zhang W; Yang D; Ning Y; Sunakawa Y; Okazaki S; Berger MD; Miyamato Y; Parekh A; Stintzing S; Loupakis F; Lenz HJ
Clin Cancer Res; 2016 Jul; 22(13):3218-26. PubMed ID: 26839145
[TBL] [Abstract][Full Text] [Related]
20. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]